The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
In vivo tumor targeting of tumor necrosis factor-α-loaded stealth nanoparticles: Effect of MePEG molecular weight and particle size
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Nanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039
Biodegradable Long-Circulating Polymeric Nanospheres
Gref, R., Minamitake, Y., Peracchia, M. T., Trubetskoy, V., Torchilin, V., & Langer, R. (1994) · Science · doi:10.1126/science.8128245 · Cited by 2,920
Mosqueira, V. C. F., Legrand, P., Gulik, A., Bourdon, O., Gref, R., Labarre, D., & Barratt, G. (2001) · Biomaterials · doi:10.1016/s0142-9612(01)00043-6 · Cited by 325
Mosqueira, V. C. F., Legrand, P., Morgat, J.-L., Vert, M., Mysiakine, E., Gref, R., Devissaguet, J.-P., & Barratt, G. (2001) · Pharmaceutical Research · doi:10.1023/a:1012248721523 · Cited by 289
Gaur, U., Sahoo, S. K., De, T. K., Ghosh, P. C., Maitra, A., & Ghosh, P. K. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00447-0 · Cited by 267
Avgoustakis, K. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00224-2 · Cited by 211
Vittaz, M., Bazile, D., Spenlehauer, G., Verrecchia, T., Veillard, M., Puisieux, F., & Labarre, D. (1996) · Biomaterials · doi:10.1016/0142-9612(95)00322-3 · Cited by 193
Peracchia, M. T., Vauthier, C., Passirani, C., Couvreur, P., & Labarre, D. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00539-0 · Cited by 175
Sadzuka, Y., Nakade, A., Hirama, R., Miyagishima, A., Nozawa, Y., Hirota, S., & Sonobe, T. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00075-3 · Cited by 139
Cited by
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Drug delivery and nanoparticles: Applications and hazards
de Jong (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s596 · Cited by 3,848
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Reddy, L. H., Arias, J. L., Nicolas, J., & Couvreur, P. (2012) · Chemical Reviews · doi:10.1021/cr300068p · Cited by 2,010
Immunological properties of engineered nanomaterials
Dobrovolskaia, M. A., & McNeil, S. E. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.223 · Cited by 1,823
Aggarwal, P., Hall, J. B., McLeland, C. B., Dobrovolskaia, M. A., & McNeil, S. E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.009 · Cited by 1,791
Mediating Tumor Targeting Efficiency of Nanoparticles Through Design
Perrault, S. D., Walkey, C., Jennings, T., Fischer, H. C., & Chan, W. C. W. (2009) · Nano Letters · doi:10.1021/nl900031y · Cited by 1,513
Nanoparticles for drug delivery: The need for precision in reporting particle size parameters
Gaumet, M., Vargas, A., Gurny, R., & Delie, F. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.08.001 · Cited by 1,081
Magnetic nanoparticles for theragnostics
Shubayev, V. I., Pisanic, T. R., & Jin, S. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.007 · Cited by 1,028
Dobrovolskaia, M. A., Aggarwal, P., Hall, J. B., & McNeil, S. E. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800032f · Cited by 1,022
Ernsting, M. J., Murakami, M., Roy, A., & Li, S.-D. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.013 · Cited by 1,012
Kulkarni, S. A., & Feng, S.-S. (2013) · Pharmaceutical Research · doi:10.1007/s11095-012-0958-3 · Cited by 768
A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics
Steichen, S. D., Caldorera-Moore, M., & Peppas, N. A. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.12.006 · Cited by 751
Perrault, S. D., & Chan, W. C. W. (2009) · Journal of the American Chemical Society · doi:10.1021/ja907069u · Cited by 658
Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects
Scioli Montoto, S., Muraca, G., & Ruiz, M. E. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.587997 · Cited by 652
PEG — A versatile conjugating ligand for drugs and drug delivery systems
Kolate, A., Baradia, D., Patil, S., Vhora, I., Kore, G., & Misra, A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.046 · Cited by 648
Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery
van Vlerken, L. E., Vyas, T. K., & Amiji, M. M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9284-6 · Cited by 645
Perry, J. L., Reuter, K. G., Kai, M. P., Herlihy, K. P., Jones, S. W., Luft, J. C., Napier, M., Bear, J. E., & DeSimone, J. M. (2012) · Nano Letters · doi:10.1021/nl302638g · Cited by 606
Rosenholm, J. M., Sahlgren, C., & Lindén, M. (2010) · Nanoscale · doi:10.1039/c0nr00156b · Cited by 572
Zhang, G., Yang, Z., Lu, W., Zhang, R., Huang, Q., Tian, M., Li, L., Liang, D., & Li, C. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2008.12.038 · Cited by 563
García, K. P., Zarschler, K., Barbaro, L., Barreto, J. A., O'Malley, W., Spiccia, L., Stephan, H., & Graham, B. (2014) · Small · doi:10.1002/smll.201303540 · Cited by 519
Cellular responses to nanoparticles: Target structures and mechanisms
Unfried, K., Albrecht, C., Klotz, L.-O., Von Mikecz, A., Grether-Beck, S., & Schins, R. P. F. (2007) · Nanotoxicology · doi:10.1080/00222930701314932 · Cited by 503
Rijcken, C. J. F., Soga, O., Hennink, W. E., & Nostrum, C. F. V. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.03.023 · Cited by 487
More Effective Nanomedicines through Particle Design
Wang, J., Byrne, J. D., Napier, M. E., & DeSimone, J. M. (2011) · Small · doi:10.1002/smll.201100442 · Cited by 466
Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy
Dong, S. (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s2824 · Cited by 464
Effect of physicochemical and surface properties on in vivo fate of drug nanocarriers
Zhao, Z., Ukidve, A., Krishnan, V., & Mitragotri, S. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.002 · Cited by 444
Stealth Coating of Nanoparticles in Drug-Delivery Systems
Fam, S. Y., Chee, C. F., Yong, C. Y., Ho, K. L., Mariatulqabtiah, A. R., & Tan, W. S. (2020) · Nanomaterials · doi:10.3390/nano10040787 · Cited by 422
RNAi-based therapeutics and tumor targeted delivery in cancer
Kara, G., Calin, G. A., & Ozpolat, B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114113 · Cited by 411
Nanoparticle Characterization: State of the Art, Challenges, and Emerging Technologies
Cho, E. J., Holback, H., Liu, K. C., Abouelmagd, S. A., Park, J., & Yeo, Y. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300697h · Cited by 382
Does a targeting ligand influence nanoparticle tumor localization or uptake?
Pirollo, K. F., & Chang, E. H. (2008) · Trends in Biotechnology · doi:10.1016/j.tibtech.2008.06.007 · Cited by 347
Questioning the use of PEGylation for drug delivery
Verhoef, J. J. F., & Anchordoquy, T. J. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0176-5 · Cited by 342
Non-viral vectors for RNA delivery
Yan, Y., Liu, X.-Y., Lu, A., Wang, X.-Y., Jiang, L.-X., & Wang, J.-C. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.008 · Cited by 332
Towards clinically translatable in vivo nanodiagnostics
Park, S.-M., Aalipour, A., Vermesh, O., Yu, J. H., & Gambhir, S. S. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.14 · Cited by 327
Assessment of PEG on polymeric particles surface, a key step in drug carrier translation
Rabanel, J.-M., Hildgen, P., & Banquy, X. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.017 · Cited by 318
Building nanostructures using RAFT polymerization
Boyer, C., Stenzel, M. H., & Davis, T. P. (2011) · Journal of Polymer Science Part A: Polymer Chemistry · doi:10.1002/pola.24482 · Cited by 314
PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00174 · Cited by 313
Nanoparticles and innate immunity: new perspectives on host defence
Boraschi, D., Italiani, P., Palomba, R., Decuzzi, P., Duschl, A., Fadeel, B., & Moghimi, S. M. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.013 · Cited by 310
Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance
Zamboni, W. C., Torchilin, V., Patri, A. K., Hrkach, J., Stern, S., Lee, R., Nel, A., Panaro, N. J., & Grodzinski, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2938 · Cited by 275
Pearce, A. K., & O’Reilly, R. K. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00456 · Cited by 275
Maldiney, T., Richard, C., Seguin, J., Wattier, N., Bessodes, M., & Scherman, D. (2011) · ACS Nano · doi:10.1021/nn101937h · Cited by 272
The protein corona and its effects on nanoparticle-based drug delivery systems
Li, H., Wang, Y., Tang, Q., Yin, D., Tang, C., He, E., Zou, L., & Peng, Q. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.019 · Cited by 265
Drug delivery of siRNA therapeutics: potentials and limits of nanosystems
Reischl, D., & Zimmer, A. (2009) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2008.06.001 · Cited by 253
Esmaeili, F., Ghahremani, M. H., Esmaeili, B., Khoshayand, M. R., Atyabi, F., & Dinarvand, R. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.07.038 · Cited by 159
PEGylated nanomedicines: recent progress and remaining concerns
Vllasaliu, D., Fowler, R., & Stolnik, S. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.866651 · Cited by 137
Ebrahim Attia, A. B., Yang, C., Tan, J. P. K., Gao, S., Williams, D. F., Hedrick, J. L., & Yang, Y.-Y. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.042 · Cited by 131
Nucleolin Targeting AS1411 Modified Protein Nanoparticle for Antitumor Drugs Delivery
Wu, J., Song, C., Jiang, C., Shen, X., Qiao, Q., & Hu, Y. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300686g · Cited by 125
Self-citationUesugi, Y., Kawata, H., Jo, J.-I., Saito, Y., & Tabata, Y. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.07.127 · Cited by 103
Wang, J., Bai, R., Yang, R., Liu, J., Tang, J., Liu, Y., Li, J., Chai, Z., & Chen, C. (2015) · Metallomics · doi:10.1039/c4mt00340c · Cited by 78
Metadata
- Authors
- Fang, C., Shi, B., Pei, Y.-Y., Hong, M.-H., Wu, J., & Chen, H.-Z.
- Venue
- European Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2006-01
- Volume
- 27
- Issue
- 1
- Pages
- 27-36
- ISSN
- 0928-0987 (ISSN-L)
- OpenAlex
- W2039201937
- Cited by
- 424
- References
- 17
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.